Recombinant lys plasminogen
Latest Information Update: 18 Nov 2003
At a glance
- Originator Nonindustrial source
- Mechanism of Action Plasminogen activator stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Arterial occlusive disorders